Company Overview
About Cambrian Bio
Cambrian Bio is a clinical-stage drug development company founded in 2019 and headquartered in New York City. The company's mission is to build medicines that redefine healthcare by developing therapeutics that prevent and treat age-related chronic diseases — extending the period of life spent in good health (healthspan). Rather than developing all drug programs in-house, Cambrian operates as a Distributed Development Company (DisCo): it provides capital, infrastructure, and strategic support to a portfolio of independent R&D teams, each advancing a program targeting a distinct biological driver of aging.
Business Model & Competitive Advantage
As of 2025, Cambrian has seven pipeline companies under its umbrella and four assets in active clinical trials. Key subsidiaries include Amplifier Therapeutics (Sweden-based, focused on AMPK activators for metabolic and cardiovascular disease, with lead asset ATX-304 in human trials), Tornado Therapeutics (next-generation rapalogs), Oviva Therapeutics (AMH/AMR2-axis therapeutics for female healthspan and ovarian reserve preservation), and Isterian Biotech (anti-fibrotic crosslink reduction compounds). Cambrian raised $30.8 million in a funding round dedicated to developing resilience-preserving therapeutics in aging populations.
Competitive Landscape 2025–2026
Cambrian Bio sits at the intersection of longevity science and clinical-stage biotech, positioning itself as a platform for translating basic aging biology research into IND-ready and clinical-stage drug candidates. Its distributed model reduces operational overhead and enables parallel progress across multiple aging biology programs, differentiating it from single-asset biotech companies in the longevity space.
Key Differentiators
Emerging Innovator
Cambrian Bio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Cambrian Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cambrian Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cambrian Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cambrian Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →